{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:29:33Z","timestamp":1786116573217,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100003347","name":"Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473381"],"award-info":[{"award-number":["82473381"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172621"],"award-info":[{"award-number":["82172621"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["23XD1420600"],"award-info":[{"award-number":["23XD1420600"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010108","name":"Zhongshan Hospital","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100015359","name":"Shanghai Medical College, Fudan University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013285","name":"Program for Professor of Special Appointment (Eastern Scholar) at Shanghai Institutions of Higher Learning","doi-asserted-by":"publisher","award":["TP2022051"],"award-info":[{"award-number":["TP2022051"]}],"id":[{"id":"10.13039\/501100013285","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003395","name":"Shanghai Municipal Education Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Med"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.medj.2026.101140","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T13:56:59Z","timestamp":1778767019000},"page":"101140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of lead-in ADT on grade \u22653 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy"],"prefix":"10.1016","volume":"7","author":[{"given":"Xudong","family":"Ni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedong","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaomeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingwei","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-6669","authenticated-orcid":false,"given":"Yao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.medj.2026.101140_bib1","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101140_bib2","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101140_bib3","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): Final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib4","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib5","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib6","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE trial","volume":"42","author":"Saad","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib7","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101140_bib8","doi-asserted-by":"crossref","first-page":"3199","DOI":"10.1200\/JCO.2015.62.3488","article-title":"Recommendations for the use of WBC growth factors: American society of clinical oncology clinical practice guideline update","volume":"33","author":"Smith","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib9","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","article-title":"Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer","volume":"28","author":"Franke","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib10","first-page":"3801","article-title":"Febrile neutropenia and its associated hospitalization in breast cancer patients on docetaxel-containing regimen: A retrospective cohort study on duration of prophylactic GCSF administration","volume":"28","author":"Lee","year":"2020","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.medj.2026.101140_bib11","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.medj.2026.101140_bib12","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1038\/s41571-022-00685-3","article-title":"Mitigating acute chemotherapy-associated adverse events in patients with cancer","volume":"19","author":"Kuderer","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib13","doi-asserted-by":"crossref","first-page":"3043","DOI":"10.1200\/JCO.18.00374","article-title":"Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update","volume":"36","author":"Taplitz","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib14","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ygyno.2012.03.015","article-title":"Predictors of severe and febrile neutropenia during primary chemotherapy for ovarian cancer","volume":"125","author":"Laskey","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib15","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1093\/annonc\/mdu203","article-title":"History of chronic comorbidity and risk of chemotherapy-induced febrile neutropenia in cancer patients not receiving G-CSF prophylaxis","volume":"25","author":"Chao","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib16","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdr493","article-title":"Validation of a predictive model that identifies patients at high risk of developing febrile neutropaenia following chemotherapy for breast cancer","volume":"23","author":"Jenkins","year":"2012","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib17","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.ejca.2015.12.009","article-title":"Severe neutropenia during cabazitaxel treatment is associated with survival benefit in men with metastatic castration-resistant prostate cancer (mCRPC): A post-hoc analysis of the TROPIC phase III trial","volume":"56","author":"Meisel","year":"2016","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.medj.2026.101140_bib18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1111\/cas.12647","article-title":"Pharmacokinetics, dynamics and toxicity of docetaxel: Why the japanese dose differs from the western dose","volume":"106","author":"Kenmotsu","year":"2015","journal-title":"Cancer Sci."},{"key":"10.1016\/j.medj.2026.101140_bib19","doi-asserted-by":"crossref","first-page":"945","DOI":"10.6004\/jnccn.2023.7044","article-title":"Real-world impact of prophylactic growth factor use on timing of febrile neutropenia and infection after high-risk chemotherapy","volume":"21","author":"Dw","year":"2023","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.medj.2026.101140_bib20","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.critrevonc.2013.12.006","article-title":"Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: A systematic review","volume":"90","author":"Lyman","year":"2014","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.medj.2026.101140_bib21","first-page":"47","article-title":"CACA guidelines for holistic integrative management of prostate cancer. Holist","volume":"3","author":"Dai","year":"2024","journal-title":"Integr. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib22","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1093\/annonc\/mdg118","article-title":"Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: A phase II study in caucasian and asian patients","volume":"14","author":"Millward","year":"2003","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib23","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10147-011-0349-5","article-title":"Pharmacoethnicity of docetaxel-induced severe neutropenia: Integrated analysis of published phase II and III trials","volume":"18","author":"Yano","year":"2013","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib24","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1200\/JCO.2002.01.025","article-title":"Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in asians through phenotyping and genotyping strategies","volume":"20","author":"Goh","year":"2002","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib29","doi-asserted-by":"crossref","first-page":"S1633","DOI":"10.1016\/j.annonc.2025.09.108","article-title":"LBA92 3-weekly docetaxel 75 mg\/m2 vs 2-weekly docetaxel 50 mg\/m2 in combination with darolutamide + ADT in patients with mHSPC: Results from the randomised phase III ARASAFE trial","volume":"36","author":"Grimm","year":"2025","journal-title":"Annals of Oncology"},{"key":"10.1016\/j.medj.2026.101140_bib25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1200\/JCO.1998.16.1.187","article-title":"Population pharmacokinetics\/pharmacodynamics of docetaxel in phase II studies in patients with cancer","volume":"16","author":"Bruno","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.medj.2026.101140_bib26","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): A multicentre, open-label, randomised, phase 3 study with a 2 \u00d7 2 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.medj.2026.101140_bib27","unstructured":"National Comprehensive Cancer Network. (2026). Clinical Practice Guidelines in Oncology: Hematopoietic Growth Factors, version 3.2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/growthfactors.pdf."},{"key":"10.1016\/j.medj.2026.101140_bib28","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2024.04.010","article-title":"EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer. Part II-2024 update: Treatment of relapsing and metastatic prostate cancer","volume":"86","author":"Tilki","year":"2024","journal-title":"Eur. Urol."}],"container-title":["Med"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001431?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666634026001431?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:52:55Z","timestamp":1786013575000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666634026001431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S2666634026001431"],"URL":"https:\/\/doi.org\/10.1016\/j.medj.2026.101140","relation":{},"ISSN":["2666-6340"],"issn-type":[{"value":"2666-6340","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of lead-in ADT on grade \u22653 neutropenia in patients with metastatic hormone-sensitive prostate cancer treated with triplet therapy","name":"articletitle","label":"Article Title"},{"value":"Med","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medj.2026.101140","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101140"}}